Probiotic composition for use in the treatment of bowel inflammation

Abstract

The present disclosure is directed to compositions comprising Lactobacillus plantarum CECT 7484, Lactobacillus plantarum CECT 7485, and Pediococcus acidilactici CECT 7483 or a mutant or variant thereof. This composition is useful in the treatment of gastrointestinal diseases or conditions such as Inflammatory Bowel Disease, Irritable Bowel Syndrome, or abdominal distension and bloating.

1 . A composition comprising  Lactobacillus plantarum  CECT 7484 and/or a mutant thereof,  Lactobacillus plantarum  CECT 7485 and/or a mutant thereof, and  Pediococcus acidilactici  CECT 7483 and/or a mutant thereof, wherein each mutant has been produced by mutagenesis. 
     
     
         2 . A composition as defined in  claim 1 , comprising  Lactobacillus plantarum  CECT 7484,  Lactobacillus plantarum  CECT 7485, and  Pediococcus acidilactici  CECT 7483. 
     
     
         3 . A probiotic product comprising the composition as defined in  claim 1 . 
     
     
         4 - 5 . (canceled) 
     
     
         6 . A method for the prevention and/or treatment of bowel inflammation in a subject, comprising administering to a subject in need thereof an effective amount of the composition as defined in  claim 1 . 
     
     
         7 . (canceled) 
     
     
         8 . A method for the prevention and/or treatment of Inflammatory Bowel Disease in a subject, comprising administering to a subject in need thereof an effective amount of the composition as defined in  claim 1 . 
     
     
         9 . A method for the prevention and/or treatment of Irritable Bowel Syndrome in a subject, comprising administering to a subject in need thereof an effective amount of the composition as defined in  claim 1 . 
     
     
         10 . A method for the prevention and/or treatment of abdominal distension and bloating in a subject, comprising administering to a subject in need thereof an effective amount of the composition as defined in  claim 1 . 
     
     
         11 . A pharmaceutical product comprising the composition as defined in  claim 1  and at least one pharmaceutically acceptable excipient. 
     
     
         12 . A veterinary product comprising the composition as defined in  claim 1  and at least one veterinary acceptable excipient. 
     
     
         13 . An edible product comprising the composition as defined in  claim 1  and at least one other edible ingredient. 
     
     
         14 . The edible product according to  claim 13 , which is a dietary supplement. 
     
     
         15 . A strain of  Lactobacillus plantarum  deposited in the Spanish Type Culture Collection under the accession number CECT 7484, or a mutant thereof, wherein the mutant has been produced by mutagenesis. 
     
     
         16 . A strain of  Lactobacillus plantarum  deposited in the Spanish Type Culture Collection under the accession number CECT 7485, or a mutant thereof, wherein the mutant has been produced by mutagenesis. 
     
     
         17 . A strain of  Pediococcus acidilactici  deposited in the Spanish Type Culture Collection under the accession number CECT 7483, or a mutant thereof, wherein the mutant has been produced by mutagenesis. 
     
     
         18 - 23 . (canceled) 
     
     
         24 . A strain of  Lactobacillus plantarum  as defined in  claim 15 , wherein the strain is a strain as deposited in the Spanish Type Culture Collection under the accession number CECT 7484. 
     
     
         25 . A strain of  Lactobacillus plantarum  as defined in  claim 16 , wherein the strain is a strain as deposited in the Spanish Type Culture Collection under the accession number CECT 7485. 
     
     
         26 . A strain of  Pediococcus acidilactici  as defined in  claim 17 , wherein the strain is a strain as deposited in the Spanish Type Culture Collection under the accession number CECT 7483.